OSE Immunotherapeutics

OSE Immunotherapeutics is a biotechnology company that focuses on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.In February 2016, the company had announced a proposed merger agreement with Effimune. The boards of directors of both OSE Pharma and Effimune had approved the proposed terms of the merger which would be submitted for approval to the shareholders during Extraordinary General Meetings that was expected to take place at the end of the second quarter of 2016. In April 2016, the companies signed the merger agreement to create OSE Immunotherapeutics on merging Effimune into OSE Pharma . Following the completion of merger, OSE Pharma and Effimune were to own 71 and 29% of capital of the merged entity, respectively. The shareholders of Effimune were to receive 1.93 newly issued shares of OSE Pharma in exchange for each 1 held share of Effimune. OSE Pharma were to be renamed as "OSE